LS Investment Advisors LLC Buys 1,155 Shares of Kenvue Inc. (NYSE:KVUE)

LS Investment Advisors LLC increased its stake in shares of Kenvue Inc. (NYSE:KVUE) by 2.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 52,450 shares of the company’s stock after buying an additional 1,155 shares during the quarter. LS Investment Advisors LLC’s holdings in Kenvue were worth $1,258,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in KVUE. HF Advisory Group LLC increased its holdings in Kenvue by 8.0% in the 1st quarter. HF Advisory Group LLC now owns 122,888 shares of the company’s stock valued at $2,947,000 after buying an additional 9,150 shares during the period. Viking Fund Management LLC boosted its position in shares of Kenvue by 33.3% during the 1st quarter. Viking Fund Management LLC now owns 400,000 shares of the company’s stock worth $9,592,000 after acquiring an additional 100,000 shares in the last quarter. Juncture Wealth Strategies LLC increased its stake in Kenvue by 9.6% in the first quarter. Juncture Wealth Strategies LLC now owns 18,314 shares of the company’s stock valued at $439,000 after acquiring an additional 1,601 shares during the last quarter. RFG Advisory LLC increased its stake in Kenvue by 34.5% in the first quarter. RFG Advisory LLC now owns 20,386 shares of the company’s stock valued at $489,000 after acquiring an additional 5,233 shares during the last quarter. Finally, Fulton Bank N.A. raised its position in Kenvue by 0.6% during the first quarter. Fulton Bank N.A. now owns 78,888 shares of the company’s stock valued at $1,892,000 after purchasing an additional 465 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Down 2.4%

NYSE:KVUE opened at $21.67 on Thursday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a one year low of $17.67 and a one year high of $25.17. The firm’s 50 day simple moving average is $23.21 and its 200 day simple moving average is $22.62. The company has a market cap of $41.58 billion, a PE ratio of 40.89, a P/E/G ratio of 2.62 and a beta of 1.02.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.24 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.01. The company had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Kenvue’s revenue was down 3.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.28 earnings per share. On average, research analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th were paid a $0.205 dividend. The ex-dividend date was Wednesday, May 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.78%. Kenvue’s payout ratio is 149.09%.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on KVUE. Citigroup raised their target price on Kenvue from $22.00 to $24.50 and gave the company a “neutral” rating in a report on Friday, May 9th. Evercore ISI assumed coverage on Kenvue in a research note on Monday, March 24th. They issued an “in-line” rating and a $25.00 price objective on the stock. UBS Group lifted their target price on Kenvue from $24.00 to $25.00 and gave the company a “neutral” rating in a research report on Friday, May 9th. Canaccord Genuity Group increased their target price on shares of Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. Finally, Piper Sandler raised their price target on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research note on Monday, February 24th. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $25.33.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.